Table 1 Association of ZDHHC15 protein expression with clinicopathological characteristics in human gliomas
From: ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma
ZDHHC15 intensity | Negative n (%) | Positive n (%) | P-value |
|---|---|---|---|
Gender | Â | Â | 0.9999 |
 Male | 55 (59.1) | 29 (58.0) |  |
 Female | 38 (40.9) | 21 (42.0) |  |
Age | Â | Â | 0.0705 |
 42< | 29 (31.2) | 8 (16.0) |  |
 ≥ 42 | 64 (68.8) | 42 (84.0) |  |
Tumor location | Â | Â | 0.4665 |
 Frontal | 29 (31.9) | 19 (41.3) |  |
 Temporal | 15 (16.5) | 5 (10.9) |  |
 Others | 47 (51.6) | 22 (47.8) |  |
Tumor size, cm3 | Â | Â | 0.0262 |
 <9.5 | 53 (57.0) | 17 (37.0) |  |
 ≥ 9.5 | 40 (43.0) | 29 (63.0) |  |
Symptoms at the diagnosis | Â | Â | 0.0423 |
 Epilepsy | 22 (23.7) | 4 (8.3) |  |
 Headache | 33 (35.5) | 14 (29.2) |  |
 Dizziness | 15 (16.1) | 11 (22.9) |  |
 Limb weakness | 7 (7.5) | 10 (20.8) |  |
 Others | 16 (17.2) | 9 (18.8) |  |
Karnofsky Performance Scale | Â | Â | 0.1288 |
 <90 | 36 (38.7) | 25 (52.1) |  |
 ≥ 90 | 57 (61.3) | 23 (47.9) |  |
Radio- and/or chemotherapy | Â | Â | 0.7447 |
 Yes | 74 (90.2) | 38 (88.4) |  |
 No | 8 (9.8) | 5 (11.6) |  |
Tumor recurrence | Â | Â | 0.1955 |
 Yes | 21(40.4) | 13 (56.5) |  |
 No | 31 (59.6) | 10 (43.5) |  |
IDH | Â | Â | 0.0047 |
 Mutate | 40 (47.1) | 11 (22.5) |  |
 Wild-type | 45 (52.9) | 38 (77.5) |  |
Ki-67 | Â | Â | 0.0075 |
 <10% | 37 (43.5) | 8 (17.0) |  |
 10–20% | 25 (29.4) | 18 (38.3) |  |
 >20% | 23 (27.1) | 21 (44.7) |  |
MGMTp methylation levels | Â | Â | 0.330 |
 Unmethylated | 23 (40.4) | 4 (26.7) |  |
 Methylated | 34 (59.6) | 11 (73.3) |  |